Info

Psychedelics Today

Psychedelics Today is the planetary leader in psychedelic education, media, and advocacy. Covering up-to-the-minute developments and diving deep into crucial topics bridging the scientific, academic, philosophical, societal, and cultural, Psychedelics Today is leading the discussion in this rapidly evolving ecosystem.
RSS Feed Subscribe in Apple Podcasts
Psychedelics Today
2024
May
April
March
February
January


2023
December
November
October
September
August
July
June
May
April
March
February
January


2022
December
November
October
September
August
July
June
May
April
March
February
January


2021
December
November
October
September
August
July
June
May
April
March
February
January


2020
December
November
October
September
August
July
June
May
April
March
February
January


2019
December
November
October
September
August
July
June
May
April
March
February
January


2018
December
November
October
September
August
July
June
May
April
March
February
January


2017
December
November
October
September
August
July
June
May
April
March
February
January


2016
December
November
October
September
August
July
June
May


Categories

All Episodes
Archives
Categories
Now displaying: Page 1
Feb 21, 2023

In this episode, Joe interviews Dr. Devon Christie: Senior Lead of Psychedelic Programs at Numinus, educator at CIIS and Vital, and MAPS-certified MDMA therapist; and Dr. Pamela Kryskow, MD: founding board member of the Psychedelic Association of Canada and Medical Lead of the nonprofit, Roots To Thrive.

Christie and Kryskow recently co-authored one of the first papers looking at MDMA for chronic pain, “MDMA-assisted therapy is associated with a reduction in chronic pain among people with post-traumatic stress disorder,” which came about after they received access to MAPS’ Phase 2 data from a lead-in PTSD study and noticed significant improvements in pain measurements – something the study was not looking for at all. They’re looking into where chronic pain fits within the frameworks of Western medicine and psychedelic-assisted therapy, and discuss the many reasons why MDMA should be tremendously helpful for chronic pain and other conditions that fall under the large umbrella of central sensitivity syndromes and nociplastic pain. They are currently working on a new study following the MAPS protocol that will research MDMA-assisted psychotherapy specifically for people with fibromyalgia, which some believe might be physicalized PTSD. If you’d like to contribute a tax-deductible donation, visit giving.viu.ca, select “other” from the dropdown, and type in “MDMA for Fibromyalgia.”

They talk about how research trials focus too much on the molecule while ignoring what the patient is saying; how a large percentage of physicians and patients don’t at all like the psychometrics used in measuring data; how physicians regularly use expectancy bias but research trials don’t (and how that affects results); why everyone needs to place higher importance on the biopsychosocial model; the idea of being more humble with science and using “theoretical” more often; the problems with microdosing trials; and the issues with evidence: If there isn’t sufficient evidence, why isn’t there? And what exactly would be sufficient?

www.psychedelicstoday.com

 

0 Comments
Adding comments is not available at this time.